Kennedy Ferruggia, Associate Editor

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

Andel's direct-to-employer model partners with Eli Lilly and other pharma companies to offer flexible, insurance-free GLP-1 access that benefits employers, patients, and manufacturers.

Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.

Fran Gregory, PharmD, outlines the expanding landscape of advanced therapies and the pivotal role specialty pharmacies play in bringing these complex treatments to community-based providers and patients.

Combining AI-driven insights with human-first outreach can overcome the emotional and behavioral barriers driving specialty medication nonadherence.

The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.

The once-weekly Saphnelo Pen offers adult patients with systemic lupus erythematosus a new, at-home alternative to monthly intravenous infusions, supported by robust phase 3 data.

This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.

A Harvard population health researcher presents findings linking adolescent food insecurity to a cluster of brain health risk factors.

Cannabidiol may have broader applicability across genetic developmental and epileptic encephalopathies (DEEs).

FDA approval expands teplizumab-mzwv to patients 1 year and older, helping delay type 1 diabetes onset for children with stage 2 diabetes.

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.

Despite the availability of 4 FDA-approved biologics, the majority of NMOSD patients remain on off-label rituximab.

The menopausal transition alters brain circuitry and estrogen signaling in ways that may elevate risk for Alzheimer disease.

Sex and gender differences remain critically underrepresented in traumatic brain injury clinical guidelines.

FDA clears an oral TYK2 blocker for active psoriatic arthritis, delivering strong ACR20 gains with a familiar safety profile.

Walgreens pilots hybrid pharmacists—4 days in-store, 1 day remote—seeking less burnout and more steady staffing.

Walgreens’ hybrid pharmacist pilot is delivering early positive results while serving as a foundational element of a broader workforce modernization strategy.

Walgreens’ hybrid pharmacist model combines in-store and centralized responsibilities to improve workforce flexibility.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.

This week's episode highlights new data on the newly approved oral GLP-1, orforglipron, the growing role of sports pharmacists, and FDA approval of a higher-dose regimen for spinal muscular atrophy.

Researchers shed new light on how zinc deficiency contributes to severe disease and death, pointing to a specific intracellular protein as a key mediator.